KADUNA BUSINESSMAN DRAGS EX FIANCEE’S FATHER TO COURT, DEMANDS DOWRY REFUND. (PHOTO).

Image
Kaduna businessman drags ex fiancee’s father to court, demands dowry refund A businessman, Nasiru Dayyabu, on Wednesday, dragged the father of his ex-fiance, Mallam Sani Direba, to Shari’a Court II sitting at Magajin Gari, Kaduna over N260,000 dowry. The complainant had joined Direba in the suit against two brothers demanding a refund of N250, 000 dowry and N10,000 introduction money he paid to marry his daughter. Represented by his counsel, Mr Sani Sunusi, the complainant told the court that he sent his people from Karaye, Kano State to Kaduna in 2025, to seek for the defendant’s daughter’s hand in marriage. “We paid the dowry and the introduction money (kudin gausuwa) and were waiting for them to set a date for the wedding,” he said. “Unfortunately, the lady’s father called to inform us that they have cancelled the marriage.” The counsel said the complainant had asked for the refund of his money since Sept. 2025 but all the efforts he made proved abortive. He claimed that his client ...

EU REGULATOR APPROVES INJECTABLE HIV DRUG AIMED AT PREVENTING TRANSMISSION. (PHOTO).


 EU regulator approves injectable HIV drug aimed at preventing transmission

The European Medicines Agency has recommended the approval of a twice-yearly injectable drug designed to prevent HIV infection, a development that researchers believe could significantly curb transmission of the virus. The drug, lenacapavir, which will be marketed in Europe under the name Yeytuo by Gilead Sciences, was described by the agency as “highly effective” and of “major public health interest.” If the European Commission accepts this guidance, the authorization will apply across all 27 EU countries, as well as Iceland, Norway, and Liechtenstein. Clinical studies conducted last year showed that lenacapavir, already used to treat individuals living with HIV, was almost 100% effective in preventing transmission in both men and women.


Public health officials, including Winnie Byanyima, the executive director of the United Nations AIDS agency, have described lenacapavir as a potential game changer in the fight against HIV, provided that it is made widely accessible. The drug, which was authorized for prevention by the U.S. Food and Drug Administration in June, has also been recommended by the World Health Organization as an additional option for people at risk. Unlike daily preventive pills or cabotegravir injections that must be administered every two months, lenacapavir provides protection for six months with a single injection, a feature that could appeal to those who prefer fewer clinic visits and less stigma. Despite its promise, critics have expressed concerns that Gilead’s plan to allow generic production in 120 low-income countries does not cover much of Latin America, where HIV rates, though lower, are rising. UNAIDS estimates that more than 40 million people worldwide live with HIV, with about 630,000 deaths from AIDS-related illnesses reported last year, and has urged global leaders, including President Donald Trump, to work toward making this long-lasting prevention option accessible to those who need it most.


Comments

Popular posts from this blog

SHAKIRA COVERS WOMEN'S HEALTH MAGAZINE,APRIL ISSUE.

THE NEW OONI OF ILE-IFE,WILL NOT EAT THE HEART OF THE LATE OONI-PALACE CHIEFS.

INNOSON GIVES OUT BRAND NEW IVM G5 AND SALARY FOR LIFE TO THE MAN WHO PROPHESIED ABOUT HIS VEHICLE MANUFACTURING IN 1979.(PHOTO).